LRRK2 and Parkinson disease: LRRK2 kinase activity is not only enhanced by LRRK2 PD mutations, but also by mutations in VPS35 (Mir et al., 2018), another cause of clinically-typical, late-onset PD (Vilariño-Güell et al., 2011; Zimprich et al., 2011).